Clinical Trials
4 trialsNCT03601442 2026-04-23
Managed Access Programs for CTL019, Tisagenlecleucel
Novartis
Available
NCT05918913 2025-09-05
Expanded Access Program for Revumenib
Syndax Pharmaceuticals
No longer available
NCT03501615 2020-06-29
MOXE
AstraZeneca
Approved for marketing
NCT03114228 2019-10-15
An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML)
Novartis
No longer available